Mechanism of nanoparticle-induced hypersensitivity in pigs: complement or not complement?

Drug Discovery Today

Volumn 23, Issue 3, 2018, Pages 487-492

  Szebeni, János ^a,b  

^a SeroScience Ltd   (Hungary)

^b UNIVERSITY OF MISKOLC   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; NANOPARTICLE; POLYSTYRENE; ANAPHYLATOXIN; MICROSPHERE; POLYSTYRENE DERIVATIVE;

ALLERGIC REACTION; ALLERGY; COMPLEMENT ACTIVATION; COMPLEMENT INDEPENDENT PSEUDOALLERGY; LUNG ALVEOLUS MACROPHAGE; NONHUMAN; PHAGOCYTOSIS; PIG; PLASMA CLEARANCE; PULMONARY INTRAVASCULAR MACROPHAGE; SHORT SURVEY; ANIMAL; CHEMISTRY; DRUG EFFECT; DRUG HYPERSENSITIVITY; HUMAN; IMMUNOLOGY;

ANAPHYLATOXINS; ANIMALS; COMPLEMENT ACTIVATION; DRUG HYPERSENSITIVITY; HUMANS; MICROSPHERES; NANOPARTICLES; POLYSTYRENES; SWINE;

EID: 85041173599     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2018.01.025     Document Type: Short Survey

References (50)

1. Szebeni, J., et al. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 99 (1999), 2302–2309.
2. Szebeni, J., et al. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am. J. Physiol. 279 (2000), H1319–1328.
3. Bodo, M., et al. Cerebrovascular involvement in liposome-induced cardiopulmonary distress in pigs. J. Liposome Res. 15 (2005), 3–14.
4. Szebeni, J., et al. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am. J. Physiol. Heart Circ. Physiol. 290 (2006), H1050–H1058.
5. Szebeni, J., et al. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. Nanomedicine 8 (2012), 176–184.
6. Szebeni, J., et al. Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model. J. Control. Release 160 (2012), 382–387.
7. Szebeni, J., et al. A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines. Adv. Drug Deliv. Rev. 64 (2012), 1706–1716.
8. Urbanics, R., Szebeni, J., Lessons learned from the porcine CARPA model: constant and variable responses to different nanomedicines and administration protocols. Eur. J. Nanomed. 7 (2015), 219–231.
9. Jackman, J.A., et al. Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: foundation of a validatable immune toxicity model. Nanomedicine 12 (2016), 933–943.
10. Hugli, T.E., et al. Possible role of serum anaphylatoxins in hypersensitivity reactions. Int. Arch. Allergy Appl. Immunol. 66:Suppl. 1 (1981), 113–120.
11. Marceau, F., et al. Effects of anaphylatoxins on circulation. Immunopharmacology 14 (1987), 67–84.
12. Szebeni, J., Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs and radiocontrast agents. Crit. Rev. Ther. Drug Carrier Syst. 18 (2001), 567–606.
13. Szebeni, J., Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216 (2005), 106–121.
14. Szebeni, J., Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol. Immunol. 61 (2014), 163–173.
15. Csukas, D., et al. Pulmonary intravascular macrophages: prime suspects as cellular mediators of porcine CARPA. Eur. J. Nanomed. 7 (2015), 27–36.
16. Wibroe, P.P., et al. Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes. Nat. Nanotechnol. 12 (2017), 589–594.
17. Al-Hanbali, O., et al. Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption. J. Nanosci. Nanotechnol. 6 (2006), 3126–3133.
18. Fernandez, H.N., Hugli, T.E., Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide portions of human C5a. J. Immunol. 117 (1876), 1688–1694.
19. Wetsel, R.A., Structure, function and cellular expression of complement anaphylatoxin receptors. Curr. Opin. Immunol. 7 (1995), 48–53.
20. Szebeni, J., et al. Complement activation during hemorrhagic shock and resuscitation in swine. Shock 20 (2003), 347–355.
21. Dobrovolskaia, M.A., McNeil, S.E., Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics. Expert Opin. Drug Deliv. 12 (2015), 1163–1175.
22. Dobrovolskaia, M.A., et al. Current understanding of interactions between nanoparticles and the immune system. Toxicol. Appl. Pharmacol. 299 (2016), 78–89.
23. Aderem, A., Underhill, D.M., Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol. 17 (1999), 593–623.
24. Epstein-Barash, H., et al. Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death. J. Control. Release 146 (2010), 182–195.
25. Gabizon, A., et al. Pharmacokinetics of PEGylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42 (2003), 419–436.
26. Ishida, T., et al. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J. Control. Release 105 (2005), 305–317.
27. Ishida, T., et al. Accelerated clearance of a second injection of PEGylated liposomes in mice. Int. J. Pharm. 255 (2003), 167–174.
28. Koide, H., et al. Particle size-dependent triggering of accelerated blood clearance phenomenon. Int. J. Pharm. 362 (2008), 197–200.
29. Ishida, T., Kiwada, H., Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Pharm. 354 (2008), 56–62.
30. Abu Lila, A.S., et al. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J. Control. Release 172 (2013), 38–47.
31. Suzuki, T., et al. Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin. Int. J. Pharm. 476 (2014), 205–212.
32. Szebeni, J., Challenges and risks of nanotechnology in medicine: an immunologist's point of view. Mueller, B., Van de Voorde, M., (eds.) Nanotechnology for Human Health, 1st ed., 2017, Wiley, 97–123.
33. Abu Lila, A.S., et al. Accelerated blood clearance phenomenon and complement activation-related pseudoallergy: two sides of the same coin. Bawa, R., et al. (eds.) Immune Effects of Biopharmaceuticals and Nanomedicines, 2018, Pan Stanford Publishing In press.
34. Verresen, L., et al. Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Kidney Int. 45 (1994), 1497–1503.
35. Blais, C. Jr., et al. Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. Peptides 20 (1999), 421–430.
36. Coppo, R., Amore, A., Importance of the bradykinin-nitric oxide synthase system in the hypersensitivity reactions of chronic haemodialysis patients. Nephrol. Dial. Transpl. 15 (2000), 1288–1290.
37. Lundberg, C., et al. C5a-induced hemodynamic and hematologic changes in the rabbit: Role of cyclooxygenase products and polymorphonuclear leukocytes. Am. J. Pathol. 128 (1987), 471–483.
38. Mousli, M., et al. A mechanism of action for anaphylatoxin C3a stimulation of mast cells. J. Immunol. 148 (1992), 2456–2461.
39. Dervadevics, M., et al. Ragweed allergy: correlation between skin reactivity and in vitro complement activation. Immunol. Lett. 64 (1998), 119–123.
40. Chanan-Khan, A., et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann. Oncol. 14 (2003), 1430–1437.
41. van der Kolk, L.E., et al. Complement activation plays a key role in the side-effects of rituximab treatment. Br. J. Haematol. 115 (2001), 807–811.
42. Benoit, Y., et al. Hypersensitivity reactions to Althesin infusion: measurement of complement involvement. Anaesthesia 38 (1983), 1079–1081.
43. del Balzo, U., et al. Cardiac anaphylaxis: Complement activation as an amplification system. Circ. Res. 65 (1989), 847–857.
44. Hakim, R.M., et al. Complement activation and hypersensitivity reactions to dialysis membranes. N. Engl. J. Med. 311 (1984), 878–882.
45. Lemke, H.D., et al. Hypersensitivity reactions during haemodialysis: role of complement fragments and ethylene oxide antibodies. Nephrol. Dial. Transpl. 5 (1990), 264–269.
46. Szebeni, J., et al. Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br. J. Pharmacol. 172 (2015), 5025–5036.
47. Macdougall, I.C., Vernon, K., Complement activation-related pseudo-allergy: a fresh look at hypersensitivity reactions to intravenous iron. Am. J. Nephrol. 45 (2017), 60–62.
48. Szebeni, J., Hypersensitivity reactions to radiocontrast media: the role of complement activation. Curr. Allergy Asthma Rep. 4 (2004), 25–30.
49. Stimler-Gerard, N.P., Role of the complement anaphylatoxins in inflammation and hypersensitivity reactions in the lung. Surv. Synth. Pathol. 4 (1985), 423–442.
50. Basta, M., et al. F (ab)′ 2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat. Med. 9 (2003), 431–438.